AU2013237275B2 - Process for determining the susceptibility to nosocomial infections - Google Patents
Process for determining the susceptibility to nosocomial infections Download PDFInfo
- Publication number
- AU2013237275B2 AU2013237275B2 AU2013237275A AU2013237275A AU2013237275B2 AU 2013237275 B2 AU2013237275 B2 AU 2013237275B2 AU 2013237275 A AU2013237275 A AU 2013237275A AU 2013237275 A AU2013237275 A AU 2013237275A AU 2013237275 B2 AU2013237275 B2 AU 2013237275B2
- Authority
- AU
- Australia
- Prior art keywords
- scd127
- patient
- sample
- expression
- septic shock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010011409 Cross infection Diseases 0.000 title claims abstract description 102
- 238000000034 method Methods 0.000 title claims abstract description 45
- 230000008569 process Effects 0.000 title claims abstract description 33
- 108010082017 alpha chain interleukin-7 receptor Proteins 0.000 claims abstract description 84
- 230000014509 gene expression Effects 0.000 claims abstract description 73
- 239000012472 biological sample Substances 0.000 claims abstract description 34
- 238000005259 measurement Methods 0.000 claims abstract description 30
- 239000000523 sample Substances 0.000 claims description 64
- 206010029803 Nosocomial infection Diseases 0.000 claims description 56
- 206010040070 Septic Shock Diseases 0.000 claims description 53
- 230000036303 septic shock Effects 0.000 claims description 53
- 230000008718 systemic inflammatory response Effects 0.000 claims description 34
- 206010040047 Sepsis Diseases 0.000 claims description 21
- 208000014674 injury Diseases 0.000 claims description 16
- 238000001356 surgical procedure Methods 0.000 claims description 16
- 230000002459 sustained effect Effects 0.000 claims description 16
- 230000008733 trauma Effects 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 238000011002 quantification Methods 0.000 claims description 8
- 238000005070 sampling Methods 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 3
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 16
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 10
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 7
- 108010058597 HLA-DR Antigens Proteins 0.000 description 7
- 239000013074 reference sample Substances 0.000 description 7
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102000000704 Interleukin-7 Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 239000002250 absorbent Substances 0.000 description 5
- 230000002745 absorbent Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B15/00—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00
- B29B15/08—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00 of reinforcements or fillers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
- B29C35/0266—Local curing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
- B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
- B29C70/06—Fibrous reinforcements only
- B29C70/10—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres
- B29C70/16—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres using fibres of substantial or continuous length
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
- B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
- B29C70/28—Shaping operations therefor
- B29C70/30—Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core
- B29C70/38—Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
- B29C70/382—Automated fiber placement [AFP]
- B29C70/384—Fiber placement heads, e.g. component parts, details or accessories
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
- B29C2035/0211—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould resistance heating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C53/00—Shaping by bending, folding, twisting, straightening or flattening; Apparatus therefor
- B29C53/56—Winding and joining, e.g. winding spirally
- B29C53/58—Winding and joining, e.g. winding spirally helically
- B29C53/581—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material
- B29C53/582—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material comprising reinforcements, e.g. wires, threads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2101/00—Use of unspecified macromolecular compounds as moulding material
- B29K2101/10—Thermosetting resins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/24—Condition, form or state of moulded material or of the material to be shaped crosslinked or vulcanised
- B29K2105/243—Partially cured
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Robotics (AREA)
- Thermal Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Materials Engineering (AREA)
- Peptides Or Proteins (AREA)
- Manufacturing & Machinery (AREA)
- Polymers & Plastics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1252641 | 2012-03-23 | ||
| FR1252641A FR2988479B1 (fr) | 2012-03-23 | 2012-03-23 | Procede de determination de la susceptibilite aux infections nosocomiales |
| PCT/FR2013/050624 WO2013140103A1 (fr) | 2012-03-23 | 2013-03-22 | Procédé de détermination de la susceptibilité aux infections nosocomiales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013237275A1 AU2013237275A1 (en) | 2014-10-02 |
| AU2013237275B2 true AU2013237275B2 (en) | 2018-07-05 |
Family
ID=48237069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013237275A Ceased AU2013237275B2 (en) | 2012-03-23 | 2013-03-22 | Process for determining the susceptibility to nosocomial infections |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9823239B2 (https=) |
| EP (1) | EP2828657B9 (https=) |
| JP (2) | JP6162788B2 (https=) |
| CN (1) | CN104246499B (https=) |
| AU (1) | AU2013237275B2 (https=) |
| BR (1) | BR112014023387B1 (https=) |
| ES (1) | ES2573807T3 (https=) |
| FR (1) | FR2988479B1 (https=) |
| WO (1) | WO2013140103A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
| FR3010792B1 (fr) * | 2013-09-18 | 2017-03-17 | Biomerieux Sa | Procede d'evaluation du risque de mortalite chez les patients qui presentent une reponse inflammatoire systemique (sirs) ou des syndromes septiques |
| FR3044325B1 (fr) * | 2015-12-01 | 2019-05-03 | Biomerieux | Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs) |
| CN108922620A (zh) * | 2018-06-20 | 2018-11-30 | 南华大学 | 一种手术切口感染风险评估系统 |
| FR3112207A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient |
| FR3112208A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient |
| FR3112209A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de complication chez un patient |
| FR3112211A1 (fr) * | 2020-07-06 | 2022-01-07 | bioMérieux | Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2941240A1 (fr) * | 2009-01-19 | 2010-07-23 | Biomerieux Sa | Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| AU629958B2 (en) * | 1989-06-15 | 1992-10-15 | Immunex Corporation | Interleukin-7 receptors |
| US20090215895A1 (en) * | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| ZA200701662B (en) * | 2004-07-27 | 2009-06-24 | Medmined Inc | Method for measuring the incidence of hospital acquirede infections |
| US20100035240A1 (en) * | 2004-08-10 | 2010-02-11 | Cardiff Biologicals Limited | Methods and kit for the prognosis of breast cancer |
| DE102008000715B9 (de) * | 2008-03-17 | 2013-01-17 | Sirs-Lab Gmbh | Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen |
| UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| CA2740191A1 (en) * | 2008-10-09 | 2010-04-15 | Thomas Ryan | A method of estimating risk of severe sepsis in an individual with infection |
| CN102301008B (zh) * | 2009-01-19 | 2015-05-13 | 生物梅里埃公司 | 用于确定患者发生医院内感染的易感性以及确立败血性综合征进展的预后的方法 |
| FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
| EP2941240A1 (en) * | 2013-01-03 | 2015-11-11 | Unilever PLC | Hair care composition |
-
2012
- 2012-03-23 FR FR1252641A patent/FR2988479B1/fr active Active
-
2013
- 2013-03-22 BR BR112014023387-0A patent/BR112014023387B1/pt not_active IP Right Cessation
- 2013-03-22 EP EP13719912.1A patent/EP2828657B9/fr active Active
- 2013-03-22 WO PCT/FR2013/050624 patent/WO2013140103A1/fr not_active Ceased
- 2013-03-22 ES ES13719912.1T patent/ES2573807T3/es active Active
- 2013-03-22 CN CN201380016796.3A patent/CN104246499B/zh not_active Expired - Fee Related
- 2013-03-22 JP JP2015500971A patent/JP6162788B2/ja not_active Expired - Fee Related
- 2013-03-22 US US14/387,076 patent/US9823239B2/en not_active Expired - Fee Related
- 2013-03-22 AU AU2013237275A patent/AU2013237275B2/en not_active Ceased
-
2017
- 2017-06-15 JP JP2017117517A patent/JP6458087B2/ja not_active Expired - Fee Related
- 2017-10-18 US US15/786,755 patent/US10725029B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2941240A1 (fr) * | 2009-01-19 | 2010-07-23 | Biomerieux Sa | Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale. |
Non-Patent Citations (1)
| Title |
|---|
| CAROLINE LANDELLE ET AL, INTENSIVE CARE MEDICINE, SPRINGER, BERLIN, DE, (2010-07-23), vol. 36, no. 11, ISSN 1432-1238, pages 1859 - 1866 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015513097A (ja) | 2015-04-30 |
| US20150064728A1 (en) | 2015-03-05 |
| BR112014023387A2 (https=) | 2017-06-20 |
| CN104246499B (zh) | 2017-05-10 |
| US20180111342A1 (en) | 2018-04-26 |
| JP6162788B2 (ja) | 2017-07-12 |
| US10725029B2 (en) | 2020-07-28 |
| ES2573807T3 (es) | 2016-06-10 |
| CN104246499A (zh) | 2014-12-24 |
| BR112014023387B1 (pt) | 2022-05-17 |
| FR2988479B1 (fr) | 2014-12-19 |
| JP2017198692A (ja) | 2017-11-02 |
| WO2013140103A1 (fr) | 2013-09-26 |
| EP2828657B9 (fr) | 2016-08-24 |
| EP2828657A1 (fr) | 2015-01-28 |
| EP2828657B1 (fr) | 2016-03-16 |
| JP6458087B2 (ja) | 2019-01-23 |
| US9823239B2 (en) | 2017-11-21 |
| AU2013237275A1 (en) | 2014-10-02 |
| FR2988479A1 (fr) | 2013-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10725029B2 (en) | Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample | |
| CN102203619B (zh) | 慢性肾病中的预测方法 | |
| Perriard et al. | Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes | |
| Liang et al. | Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73 | |
| Osterburg et al. | NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline | |
| Tinholt et al. | Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells | |
| Lima et al. | Low thymic output in the 22q11. 2 deletion syndrome measured by CCR9+ CD45RA+ T cell counts and T cell receptor rearrangement excision circles | |
| WO2018224506A2 (en) | Auto immune diagnosis using t cell populations | |
| US20200256876A1 (en) | KIT FOR IN VITRO OR EX VIVO MEASUREMENT OF THE EXPRESSION OF sCD127 IN A BIOLOGICAL SAMPLE | |
| Bunting et al. | CCR6 supports migration and differentiation of a subset of DN1 early thymocyte progenitors but is not required for thymic nTreg development | |
| Subhi‐Issa et al. | Myeloid‐derived suppressor cells as a potential biomarker for recurrent pregnancy loss and recurrent implantation failure: Increased levels of MDSCs in recurrent reproductive failure | |
| Bahabayi et al. | Reduced TRIM expression correlates with anomalous CD4 T cell activation in systemic lupus Erythematosus and its clinical diagnostic potential | |
| Heiba et al. | Plasma interleukin-22 and its cellular receptor (IL-22RA1) expression in chronic lymphocytic leukemia | |
| US20230168243A1 (en) | Methods for diagnosing immediate hypersensitivy reaction | |
| Matsunaga et al. | Long-term follow-up of production of IgM and IgG antibodies against SARS-CoV-2 among patients with COVID-19 | |
| Maulicino | Investigating the Role of Immune Response Markers in Predicting Severity and Prognosis in COVID-19 Patients: A Retrospective Study from the ASL1 Emergency Department | |
| Du et al. | Simultaneous detection of serum immunoglobulin G antibodies to Cryptosporidium parvum by multiplex microbead immunoassay using 3 recognized specific recombinant C. parvum antigens | |
| WO2022258252A1 (en) | Biomarker for monitoring coronavirus disease 2019 | |
| Bienzle et al. | American Society for Veterinary Clinical Pathology (ASVCP) 46th Annual Meeting | |
| WO2010099568A1 (en) | Biomarkers for chronic fatigue syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |